PROGRAM
CO-CHAIRPERSONS
Lingshi
TAN, PhDGeneral Manager, Pfizer (China) R&D Co., Ltd. Vice
President, Pfizer Worldwide Development Operations, China
Yajun
ZHAODirector-General, China Center for Pharmaceutical
International Exchange(CCPIE), China
PROGRAM VICE
CHAIRPERSON
Dayao ZHAO, MD,
PhDVice President, Janssen Pharmaceutical Research &
Development Head of China Research & Development and Scientific
Affairs
|
|
ANNUAL
MEETING THEME SNAPSHOT
- Chemistry, Manufacturing and Controls (CMC) /cGMP
- Clinical Research and Operations
- Data Management
- Drug Safety and Pharmacovigilance
- Regulatory Science
- Statistics
- The Pathway to Success for CROs and SMOs in China
- Vaccines and Biologics
New Programs:
- SFDA Town Hall Meeting
- Regulatory and Drug Safety Joint Session: Balancing Risk and Benefit during
NDA and Post Marketing Periods
- Botanical Drug Products in China and the United States
- Future Oncology Drug Development: Opportunities and Challenges
- Innovation on Medical Devices and Combinational Products
- Pharmacoepidemiology – Best Practices and Drug Safety
- Pharm/Tox
- Post Approval Studies
- Development of Novel Traditional Chinese Medicines (TCMs)
PRECONFERENCE
WORKSHOPS
Maximize your learning while attending the 5th DIA China Annual
Meeting! Pre-conference workshops include:
- Analysis of Data Patterns to Monitor and Assess Outcomes of Clinical Studies
- Drug Substance and Drug Products Stability Requirements and Practice in
Early Phase Development
- Data Management for Oncology Trials
- Applying MedDRA with Clinical Safety and Pharmacovigilance Practices:
Regulatory Perspective
- Global Clinical Trials - Principles and Case Studies
LESS THAN TWO MONTHS
LEFT TO SUBMIT YOUR RESEARCH
|
|
No comments:
Post a Comment